Levodopa or dopamine agonists in the early treatment of Parkinson's disease

A. Rabinstein, W. J. Weiner

Research output: Contribution to journalArticle

Abstract

The initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease (PD) has been controversial for a long time. Although levodopa is the most effective symptomatic treatment for parkinsonism, concern regarding its potential toxicity to dopaminergic neurons and the clinical complications associated with its longterm use (particularly motor fluctuations, dyskinesias and drug-induced abnormal behavior) have fueled the search for levodopa-sparing strategies.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalFocus on Parkinson's Disease
Volume12
Issue number3
StatePublished - Oct 28 2000

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Levodopa or dopamine agonists in the early treatment of Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this